Protagonist Historical Income Statement

PTGX Stock

USD 44.95 0.12 0.27%

Historical analysis of Protagonist Therapeutics income statement accounts such as Gross Profit of 63 M, Other Operating Expenses of 90.9 M, Research Development of 72.9 M or Cost Of Revenue of 6.5 M can show how well Protagonist Therapeutics performed in making a profits. Evaluating Protagonist Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Protagonist Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Protagonist Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protagonist Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

About Protagonist Income Statement Analysis

Protagonist Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Protagonist Therapeutics shareholders. The income statement also shows Protagonist investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Protagonist Therapeutics Income Statement Chart

At this time, Protagonist Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 4.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 18 M in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Protagonist Therapeutics. It is also known as Protagonist Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Protagonist Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Protagonist Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.At this time, Protagonist Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 4.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 18 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	443K	4.1M	12.9M	13.6M
Net Interest Income	443K	4.1M	12.9M	13.6M

Interest Income Net Interest Income

Protagonist Therapeutics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Interest Income	Interest Income	Non Operating Income Net Other	Reconciled Depreciation	Tax Provision
Depreciation And Amortization		0.87	0.82	0.86	-0.89	-0.95	-0.89	0.86	-0.89	-0.06	0.86	-0.85	0.79	-0.85	-0.86	0.78	0.78	0.78	0.85	0.53
Selling General Administrative	0.87		0.76	0.99	-0.94	-0.94	-0.94	0.99	-0.94	0.06	0.99	-0.92	0.65	-0.93	-0.69	0.59	0.6	0.71	0.92	0.64
Gross Profit	0.82	0.76		0.74	-0.68	-0.81	-0.69	0.73	-0.68	0.14	0.74	-0.61	0.9	-0.62	-0.9	0.87	0.87	0.78	0.67	0.58
Other Operating Expenses	0.86	0.99	0.74		-0.96	-0.94	-0.96	1.0	-0.96	0.05	1.0	-0.95	0.61	-0.95	-0.66	0.55	0.55	0.67	0.92	0.64
Operating Income	-0.89	-0.94	-0.68	-0.96		0.96	1.0	-0.96	1.0	-0.01	-0.96	0.99	-0.6	0.99	0.65	-0.55	-0.55	-0.68	-0.93	-0.6
Net Income From Continuing Ops	-0.95	-0.94	-0.81	-0.94	0.96		0.96	-0.94	0.96	0.0	-0.94	0.93	-0.77	0.93	0.81	-0.74	-0.74	-0.78	-0.93	-0.61
Ebit	-0.89	-0.94	-0.69	-0.96	1.0	0.96		-0.96	1.0	-0.02	-0.96	0.99	-0.61	0.99	0.65	-0.55	-0.56	-0.69	-0.93	-0.61
Research Development	0.86	0.99	0.73	1.0	-0.96	-0.94	-0.96		-0.96	0.05	1.0	-0.95	0.6	-0.96	-0.65	0.53	0.54	0.66	0.92	0.64
Ebitda	-0.89	-0.94	-0.68	-0.96	1.0	0.96	1.0	-0.96		-0.02	-0.96	0.99	-0.6	0.99	0.64	-0.54	-0.55	-0.68	-0.93	-0.61
Cost Of Revenue	-0.06	0.06	0.14	0.05	-0.01	0.0	-0.02	0.05	-0.02		0.05	0.0	0.06	0.0	-0.05	0.0	0.0	0.01	-0.12	-0.09
Total Operating Expenses	0.86	0.99	0.74	1.0	-0.96	-0.94	-0.96	1.0	-0.96	0.05		-0.95	0.61	-0.95	-0.66	0.55	0.55	0.67	0.92	0.64
Income Before Tax	-0.85	-0.92	-0.61	-0.95	0.99	0.93	0.99	-0.95	0.99	0.0	-0.95		-0.51	1.0	0.56	-0.45	-0.46	-0.61	-0.91	-0.6
Total Other Income Expense Net	0.79	0.65	0.9	0.61	-0.6	-0.77	-0.61	0.6	-0.6	0.06	0.61	-0.51		-0.52	-0.98	0.98	0.98	0.9	0.65	0.36
Net Income	-0.85	-0.93	-0.62	-0.95	0.99	0.93	0.99	-0.96	0.99	0.0	-0.95	1.0	-0.52		0.57	-0.46	-0.47	-0.61	-0.92	-0.61
Income Tax Expense	-0.86	-0.69	-0.9	-0.66	0.65	0.81	0.65	-0.65	0.64	-0.05	-0.66	0.56	-0.98	0.57		-0.97	-0.96	-0.86	-0.68	-0.37
Net Interest Income	0.78	0.59	0.87	0.55	-0.55	-0.74	-0.55	0.53	-0.54	0.0	0.55	-0.45	0.98	-0.46	-0.97		1.0	0.89	0.6	0.31
Interest Income	0.78	0.6	0.87	0.55	-0.55	-0.74	-0.56	0.54	-0.55	0.0	0.55	-0.46	0.98	-0.47	-0.96	1.0		0.89	0.61	0.34
Non Operating Income Net Other	0.78	0.71	0.78	0.67	-0.68	-0.78	-0.69	0.66	-0.68	0.01	0.67	-0.61	0.9	-0.61	-0.86	0.89	0.89		0.68	0.27
Reconciled Depreciation	0.85	0.92	0.67	0.92	-0.93	-0.93	-0.93	0.92	-0.93	-0.12	0.92	-0.91	0.65	-0.92	-0.68	0.6	0.61	0.68		0.74
Tax Provision	0.53	0.64	0.58	0.64	-0.6	-0.61	-0.61	0.64	-0.61	-0.09	0.64	-0.6	0.36	-0.61	-0.37	0.31	0.34	0.27	0.74

Click cells to compare fundamentals

Protagonist Therapeutics Account Relationship Matchups

Protagonist Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	703K	789K	2.8M	3.4M	3.3M	3.5M
Interest Expense	169K	598K	2.5M	3.4M	3.9M	4.1M
Selling General Administrative	15.7M	18.6M	27.2M	31.7M	33.5M	18.0M
Total Revenue	231K	28.6M	27.4M	26.6M	60M	63M
Gross Profit	231K	28.6M	24.6M	26.6M	60M	63M
Other Operating Expenses	80.8M	93.1M	153.2M	158.0M	153.7M	90.9M
Operating Income	(80.5M)	(64.5M)	(125.8M)	(131.4M)	(93.7M)	(98.3M)
Net Income From Continuing Ops	(77.2M)	(66.2M)	(125.6M)	(127.4M)	(140.5M)	(133.5M)
Ebit	(78.4M)	(64.5M)	(125.8M)	(131.4M)	(93.7M)	(98.3M)
Research Development	65.0M	74.5M	126.0M	126.2M	120.2M	72.9M
Ebitda	(77.7M)	(63.7M)	(123.1M)	(128.0M)	(90.3M)	(94.9M)
Total Operating Expenses	80.8M	93.1M	153.2M	158.0M	153.7M	90.9M
Income Before Tax	(77.9M)	(64.8M)	(125.6M)	(127.4M)	(79.0M)	(82.9M)
Total Other Income Expense Net	2.6M	(329K)	294K	4.0M	14.7M	15.4M
Net Income Applicable To Common Shares	(77.2M)	(66.2M)	(125.6M)	(127.4M)	(114.7M)	(108.9M)
Net Income	(77.2M)	(66.2M)	(122.6M)	(123.4M)	(79.0M)	(82.9M)
Income Tax Expense	(691K)	1.3M	(2.9M)	(4.0M)	(14.9M)	(14.2M)
Net Interest Income	2.6M	302K	443K	4.1M	12.9M	13.6M
Interest Income	2.8M	900K	443K	4.1M	12.9M	13.6M
Non Operating Income Net Other	2.8M	269K	294K	4.0M	4.6M	4.8M
Reconciled Depreciation	2.5M	2.6M	2.8M	3.4M	3.3M	2.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protagonist Historical Income Statement

About Protagonist Income Statement Analysis

Protagonist Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Protagonist Therapeutics income statement Correlations

Protagonist Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protagonist Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Protagonist Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Total Operating Expenses	+ 1.0	Research Development

Income Tax Expense	- 0.98	Total Other Income Expense Net
Net Interest Income	- 0.97	Income Tax Expense
Interest Income	- 0.96	Income Tax Expense
Total Operating Expenses	- 0.96	Ebitda
Net Income	- 0.96	Research Development
Ebitda	- 0.96	Research Development